ISRCTN34555414已完成未知
European Society of Intensive Care Medicine study of therapeutic hypothermia (32 - 35°C) for intracranial pressure (ICP) reduction after traumatic brain injury
niversity of Edinburgh and NHS Lothian (UK)0 个研究点目标入组 600 人开始时间: 2008年5月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
2011 protocol in http://www.ncbi.nlm.nih.gov/pubmed/21226939 2013 results in http://www.ncbi.nlm.nih.gov/pubmed/24004918 2015 results in http://www.ncbi.nlm.nih.gov/pubmed/26444221 2018 results in http://www.ncbi.nlm.nih.gov/pubmed/30168413
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 14/08/2012:
- •1. Believed to be legal age for consent to take part in research, either sex
- •2. Primary closed traumatic brain injury
- •3. Raised ICP greater than 20 mmHg for greater than or equal to 5 minutes after first line treatments with no obvious reversible cause e.g. patient position, coughing, inadequate sedation
- •4. Less than or equal to 10 days from the initial head injury
- •5. Cooling device or technique available for greater than 48 hours
- •6. Core temperature greater than or equal to 36°C (at the time of randomisation)
- •7. An abnormal computed tomography (CT) scan of the brain. This is defined as one that shows haematoma, contusion, swelling, herniation or compressed basal cisterns.
- •Previous inclusion criteria as of 01/07/2009 and until 14/08/2012:
- •1. Believed to be legal age for consent to take part in research to 65 years of age, either sex
- •4. Less than or equal to 72 hours from the initial head injury
- •Initial information at time of registration (2008):
- •1. Adults aged 16 - 65 years, both males and females
- •2. Primary, closed traumatic brain injury
- •3. An abnormal computed tomography (CT) scan of brain, Marshall grade greater than 1
- •4. Refractory increased intracranial pressure (ICP) greater than 20 mmHg for at least 30 minutes (refractory to first line interventions including mechanical ventilation, sedation, analgesia ± muscle relaxant, head of bed elevation, with monitoring of CVP and invasive arterial pressure)
- •5. Core temperature greater than 36°C (at the time of randomisation)
- •6. Cooling device or technique available for greater than 48 hours
排除标准
- •Current information as of 01/07/2009:
- •1. Patient already receiving therapeutic hypothermia treatment
- •2. Administration of barbiturate infusion prior to randomisation
- •3. Unlikely to survive for the next 24 hours in the opinion of the ICU Consultant or Consultant Neurosurgeon treating the patient
- •4. Temperature less than or equal to 34°C at hospital admission
- •5. Pregnancy
- •Initial information at time of registration:
- •1. Patients with bilateral fixed and dilated pupils
- •2. Unable to monitor ICP or patients with ICP less than 20 mmHg
- •3. Patients who have received barbiturates prior to randomisation
- •4. Where there is documented brainstem involvement
- •5. Moribund condition on admission
研究者
相似试验
已完成
2 期
Cisplatin, capecitabine, and radiation therapy with or without cetuximab in treating patients with oesophageal cancerOesophageal cancerCancerISRCTN47718479Velindre NHS Trust (UK)420
已完成
不适用
Efficacy of an educational school-based intervention to reduce prevalence of obesity in childhood in CataloniaObesityISRCTN29247645niversity of Rovira i Virgili (Universitat Rovira i Virgili) (Spain)1,400
已完成
4 期
Standardised, Concentrated and Additional Macronutrients in neonatal Parenteral nutrition studyISRCTN76597892iverpool Women's Hospital NHS Foundation Trust (UK)150
已完成
不适用
A multicentre, prospective, randomised study of the value of a single dose of intravesical Mitomycin-C in preventing the development of bladder tumours following nephroureterectomy for transitional cell carcinoma (TCC) of the upper urinary tractpper tract TCC bladderMalignant neoplasm of bladderCancerISRCTN36343644Sussex NHS Research Consortium (UK)268
进行中(未招募)
3 期
Renal Adjuvant Multiple Arm Randomised Trial (RAMPART)Resected primary renal cell carcinomaMalignant neoplasm of kidney, except renal pelvisCancerISRCTN53348826niversity College London1,750
